TTR and cardiomyopathy: As TTR silencers currently are indicated in Canada only for ATTRv polyneuropathy, and TTR stabilizers are only indicated for ATTR cardiomyopathy, with limited evidence to support the use of these agents in combination, collaboration between cardiologists and neurologists is needed to determine the most appropriate therapy.